GHK-Cu vs AHK-Cu: One Residue Apart, Two Separate Research Literatures

Separated by a single residue — glycine or alanine in the first position — GHK-Cu and AHK-Cu are copper-binding tripeptides whose published literatures point in different directions because of that one swap. GHK-Cu (Gly-His-Lys as the copper(II) complex, CAS 89030-95-5, 403.93 g/mol) is much the better studied, dominating work on matrix biology and skin models. AHK-Cu (Ala-His-Lys, CAS 1245800-58-7, about 417.96 g/mol as the complex, INCI copper tripeptide-3) turns up almost only in hair follicle and dermal papilla research. Comparing GHK-Cu with AHK-Cu is therefore less about which is more potent than about which body of evidence your assay is designed to extend.

We supply both as lyophilized blue powders with lot-matched HPLC certificates: GHK-Cu in 50 mg, 100 mg and 200 mg vials, AHK-Cu in 50 mg and 100 mg vials. They belong to one chemical family — see the copper peptides collection — and both are research chemicals rather than therapeutic products.

A single methyl group, two bodies of evidence

Chemically the pair are close to identical. Each is a tripeptide in which the histidine imidazole and the N-terminal amine supply the main donor set for a copper(II) ion, producing the blue complex that reveals copper coordination without any instrument. Exchanging glycine for alanine adds one methyl group to the first residue: small enough to leave the copper-binding geometry intact, yet large enough to shift hydrophobicity, surface behaviour in a formulation and, at least in principle, how the N-terminus is read by any receptor or transporter.

The difference that really counts is origin rather than chemistry. Human research from the 1970s onwards identified GHK as a naturally occurring plasma tripeptide matching a sequence in collagen alpha-2(I), which is why so much of its literature belongs to matrix biology. AHK has no equivalent endogenous history; it was created as a GHK analogue and entered the record through cosmetic science and follicle studies. When a protocol needs a molecule with a described physiological counterpart, that asymmetry is decisive. For background on the class, see copper peptide in the glossary and the longer piece at What is GHK-Cu?.

Research to date

GHK-Cu in matrix, wound and skin models

The GHK-Cu literature is wide and largely preclinical. Cell culture reports describe more collagen, elastin, decorin and glycosaminoglycan production in fibroblast systems, together with changes in matrix metalloproteinases and their tissue inhibitors, a remodelling signature rather than a single-target action. Wound models in rodents and rabbits published from the 1980s onward reported quicker closure and different granulation tissue in copper-tripeptide groups compared with vehicle. Expression profiling has reported that GHK affects a great many transcripts in cultured cells, which is why reviews tend to call it a matrix signalling molecule rather than a receptor agonist. Human evidence comes mainly from cosmetic formulations, where controlled facial studies of GHK-containing creams reported measurable shifts in roughness and density readouts; those are appearance endpoints for finished cosmetics, not statements about research-grade powder.

AHK-Cu in follicle and papilla systems

AHK-Cu occupies a much narrower slice of the literature. Studies in human hair follicle organ culture report longer follicle elongation and a delayed exit from the growth phase compared with control media, while dermal papilla cell work reports greater proliferation and higher VEGF expression. Those papers interpret the findings as follicular angiogenic and papilla-supporting signalling. The evidence base is thinner, the models more specialised and independent replication limited, all of which any protocol built on it should state openly. Our fuller treatment is at What is AHK-Cu?, and the wider field is surveyed in Peptides for Hair Growth: Research Overview.

Their common ground

Both peptides are investigated as copper carriers, and a persistent methodological difficulty is telling peptide-specific signalling apart from the effect of simply supplying bioavailable copper. Copper by itself alters lysyl oxidase activity and several redox-sensitive pathways. A sound comparison therefore includes both a copper-salt control and a copper-free peptide control; without them a positive result cannot separate the tripeptide from its cargo. This applies equally to both molecules and is the most frequent flaw in copper-peptide experiments.

Choosing between them

• For collagen, elastin or extracellular matrix endpoints in fibroblast or dermal models, use GHK-Cu, since the comparison literature and assay conventions are already established there. Begin with GHK-Cu vials.
• For follicle organ culture, dermal papilla proliferation or follicular angiogenesis readouts, AHK-Cu is what the existing follicle papers used, so AHK-Cu vials keep results comparable with that work.
• For direct analogue comparisons, match molarity rather than mass: the 14 g/mol gap is small, but free-peptide and complex weights are not interchangeable. The molecular weight and molarity guide covers the calculation.
• For topical formulation science both are used, and the pre-formulated GHK-Cu + AHK-Cu Hair Serum exists for finished-format stability work rather than raw peptide chemistry.
• For multi-peptide follicle panels, the Hair Growth Stack combines both copper tripeptides with PTD-DBM for comparative screening.

Handling, stability and storage

Handling is virtually the same for both, and one shared warning outweighs any difference between them: in each case the copper complex is the active species, and strongly acidic media can break it apart. A solution that loses its blue colour has told you something about its integrity. Both peptides go into solution easily in bacteriostatic or sterile water; both are kept lyophilized at −20 °C, sealed and shielded from light and moisture; reconstituted stocks live at 2-8 °C in the dark and are used within the study period. Repeated freezing and thawing of aqueous stocks is the usual explanation for unexplained potency drift, so aliquoting at first reconstitution is standard. The practical detail is in How to Store Peptides and the reconstitution guide.

One formulation point matters for topical research: copper tripeptides are chemically incompatible with several common cosmetic actives, particularly strong reducing agents and concentrated acids, and mixing them into one vehicle can strip the copper before the peptide ever reaches the model. Formulation considerations are discussed in Topical Peptides in Cosmetic Research.

What to verify on the certificate

With copper peptides, a purity number by itself is not enough. The certificate should confirm peptide identity by mass spectrometry, give HPLC purity for the peptide component and, ideally, report copper content or the stoichiometry of the complex, because a nominally pure tripeptide that is only partly complexed will behave differently in any copper-sensitive assay. Both products here ship at ≥99% HPLC purity with a lot-matched certificate; How to Read a Peptide COA explains how to interpret one. Because lot-to-lot consistency matters most in longitudinal studies, record lot numbers with your data.

Summary for protocol selection

GHK-Cu is the benchmark copper tripeptide, with deeper literature, a known endogenous counterpart and default status for matrix and skin research. AHK-Cu is the narrower follicle-focused analogue, suitable when the aim is specifically to build on hair research. Related comparisons and family context are available through the hair research peptides collection and the skin research overview.